Don't miss our weekly PhD newsletter | Sign up now Don't miss our weekly PhD newsletter | Sign up now

  New Point of Care Diagnostic Technology for Cancer Biomarkers


   School of Chemical Engineering

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
Prof P Mendes  No more applications being accepted  Competition Funded PhD Project (UK Students Only)

About the Project

There is now overwhelming evidence that glycosylation, the process by which sugars are attached to proteins, changes during the development and progression of various malignancies. Altered glycosylation has been implicated in cancer, immune deficiencies, neurodegenerative diseases, hereditary disorders and cardiovascular diseases. Glycoproteomics is rapidly emerging as an important technique for biomarker discovery, and glycoproteins are expected to become increasingly important to the diagnosis and management of human diseases.

Currently, antibodies are playing a central role in enabling the detection of glycoprotein biomarkers. Nonetheless, antibodies do have their own set of drawbacks that limit the commercialization of antibody sensing technology. They suffer from poor stability, need special handling and require a complicated, costly production procedure. More importantly, they lack specificity and are not able to discriminate among different glycosylated proteins. The current antibody diagnostic technology has well recognized limitations regarding their accuracy and timeliness of diagnose of disease. This project will focus on research into the means of developing a generic, robust, reliable and cost-effective alternative to antibody technology. The project aims to exploit concepts and tools from nanochemistry, supramolecular chemistry and molecular imprinting to provide highly innovative synthetic recognition platforms with high sensitivity and specificity for glycoproteins.

This project will deliver an unique and genuinely world leading research activity in the development of synthetic recognition platforms that will allow for earlier, faster and accurate diagnosis of many devastating human diseases. In this project, the potential of the novel synthetic recognition platforms will be illustrated by developing a novel screening tool for diagnostic and prognostic information in the setting of renal failure in multiple myeloma, a major cause of morbidity and mortality in multiple myeloma cancer patients.

Funding Notes

A first degree (typically BSc or Masters) in Engineering, Chemistry, Material Sciences, Physics or Biology is required. Applications including CV and detailed education with grades should be addressed to Dr Paula Mendes ([Email Address Removed]).

Funding: This award is only open to UK/EU students. Overseas students are not eligible for funding.

Open Days


Project supervisors

Career overview

Professor Paula Mendes is a Professor of Advanced Materials and Nanotechnology in the School of Chemical Engineering at the University of Birmingham. She received her MSc in Chemical Engineering in 1997 and her PhD in 2002, both from the Faculty of Engineering at the University of Porto, Portugal. In 1997, she was awarded a competitive University Fellowship to conduct research in computational chemical engineering at the National Polytechnic Institute of Lorraine (INPL) in Nancy, France. Following her doctoral studies, Professor Mendes undertook post-doctoral research from 2002 to 2004 in the School of Chemistry at the University of Birmingham, UK, and subsequently from 2004 to 2006 at the Department of Chemistry and Biochemistry at the University of California, Los Angeles (UCLA), USA, under the supervision of 2016 Nobel Prize winner in Chemistry, Professor Sir Fraser Stoddart FRS. She began her academic career at the University of Birmingham in 2006 as an academic fellow and was promoted to Senior Lecturer in 2011, and then to Professor of Advanced Materials and Nanotechnology in 2013. Additionally, she served as a Visiting Professor at the University of Washington''s Department of Bioengineering in the USA from September 2015 to July 2018. Professor Mendes leads the Mendes Research Group, which focuses on interdisciplinary research in nanoscience and nanotechnology, developing methods to control the structure and functionality of materials at the molecular and nanometer scale. Her research addresses fundamental scientific questions and aims to create innovative technologies to tackle challenges in biofouling, on-demand biosensing, and molecular diagnostics, ultimately benefiting human health. She is also a member of the Healthcare Technologies Institute (HTI), collaborating with over 70 academics to advance new technologies and treatments for improved tissue healing and rehabilitation. Her contributions to the field have been recognised through numerous awards, including the European Research Council (ERC) Advanced Grant in 2024, the 2021 Institution of Chemical Engineers (IChemE) Sharma Medal, and the 2019 Women in Tech Academic Award. Professor Mendes has authored over 100 manuscripts, holds four patents, and has received prestigious research funding, including an Engineering and Physical Sciences Research Council (EPSRC) Fellowship and ERC grants. She serves as an editor for several scientific journals and is actively involved in the Institution of Chemical Engineers Research and Innovation Community of Practice.


Research interests

Professor Mendes'' research focuses on advanced materials and nanotechnology, particularly at the intersection of engineering, chemistry, and biology. She leads the Mendes Research Group, which conducts interdisciplinary research in nanoscience and nanotechnology, developing methods to control the structure and functionality of materials at the molecular and nanometer scale. Her research addresses fundamental scientific questions and aims to develop innovative technologies for biofouling prevention, on-demand biosensing, and molecular diagnostics, ultimately benefiting human health. Professor Mendes is involved in the Healthcare Technologies Institute, collaborating with over 70 academics to advance new technologies and treatments for better tissue healing and rehabilitation. Her pioneering work includes the use of electrically switchable oligopeptides for controlling biological interactions and the development of molecular-based biosensors applicable in various fields, including cell therapy bioprocessing and cancer diagnosis. She has authored over 100 manuscripts and holds multiple patents, receiving recognition through prestigious research grants and awards.

View Professor Paula Mendes's profile